Abstract
Relatively little data are available on the use of modern anti-obesity drugs in early pregnancy. There seems to be no effect of the use of orlistat but an indicated doubling of malformation risk after sibutramine which should be avoided in early pregnancy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Blomberg M, Källén B. Maternal obesity and morbid obesity: the risk for birth defects in the offspring. Birth Defects Res A Clin Mol Teratol. 2010;88:35–40.
De Santis M, Straface G, Cavaliere AF, Carducci B, Caruso A. Early first-trimester sibutramine exposure: pregnancy outcome and neonatal follow-up. Drug Saf. 2006;29:255–9.
Heinonen OP, Sloan D, Shapiro S. Birth defects and drugs in pregnancy. Littleton, MA: Publishing Sciences Group, Inc.; 1977.
Källén AJB. Antiobesity drugs in early pregnancy and congenital malformations in the offspring. Obes Res Clin Pract. 2014;8:e571–6.
Perrio MJ, Wilton LV, Shakir AW. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. Obesity. 2007;15:2712–22.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Källén, B. (2019). Maternal Use of Anti-Obesity Drugs and Infant Congenital Malformations. In: Maternal Drug Use and Infant Congenital Malformations. Springer, Cham. https://doi.org/10.1007/978-3-030-17898-7_5
Download citation
DOI: https://doi.org/10.1007/978-3-030-17898-7_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-17897-0
Online ISBN: 978-3-030-17898-7
eBook Packages: MedicineMedicine (R0)